08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Affymax management update

Affymax Inc. (OTCQB:AFFY), Cupertino, Calif.   Business: Hematology   Hired: Jonathan Couchman as president, CEO and a director, formerly CEO, CFO and chairman of Myrexis Inc.  ...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Incyte management update

Incyte Corp. (NASDAQ:INCY), Wilmington, Del.   Business: Cancer, Autoimmune, Hematology   Hired: David Gryska as EVP and CFO, effective Oct. 31, formerly COO of Myrexis Inc. ; he succeeds David Hastings  ...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Myrexis cancer news

Myrexis also said that NASDAQ initiated proceedings to delist the company due to its belief that Myrexis is a "public shell" and the resignation of all the company's independent directors. The company could not be...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

BioFire management update

BioFire Diagnostics Inc. , Salt Lake City, Utah   Business: Diagnostic, Supply/Service   Hired: Robert Lollini as CFO, formerly CEO and CFO of Myrexis Inc.  ...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

EpiCept, Myrexis deal

EpiCept said that Myrexis terminated a 2003 deal and returned rights to cancer compound Azixa verubulin to EpiCept. Myrexis discontinued development of Azixa last year. The small molecule microtubule destabilizing apoptosis-inducer was in Phase IIb...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Myrexis autoimmune, cancer news

Myrexis said CEO Richard Brewer died from multiple myeloma. He was 61. Brewer joined cancer company Myrexis in May after nearly 35 years in the biopharma industry. He served as president and CEO of Scios...
00:02 , Aug 16, 2012 |  BC Extra  |  Company News

Veteran biotech exec Brewer passes away

Myrexis Inc. (NASDAQ:MYRX) said CEO Richard Brewer died from multiple myeloma. He was 61. Brewer joined cancer company Myrexis in May after nearly 35 years in the biopharma industry. He served as president and CEO...
07:00 , May 21, 2012 |  BC Week In Review  |  Company News

Myrexis management update

Myrexis Inc. (NASDAQ:MYRX), Salt Lake City, Utah   Business: Cancer, Infectious   Hired: Richard Brewer as president, CEO and a director, formerly CEO of Scios Inc. , which Johnson & Johnson acquired; he replaces Robert...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

Myrexis cancer news

Myrexis said it would reduce headcount to 10 by June 30. The move follows a February announcement that the company retained Stifel Nicolaus Weisel to evaluate strategic alternatives and suspended development of all its preclinical...